This article is more than 5 years old. Information may no longer be current.
COMPARE
Trial of Everolimus-eluting Stents and Paclitaxel-eluting Stents for Coronary Revascularization in Daily Practice
Click Here to Manage Email Alerts
Trial compared safety and efficacy of everolimus-eluting stent vs. paclitaxel-eluting stent in patients undergoing elective or emergent PCI.
Design: randomized
Patients: 1,800
Centers: single
Countries: The Netherlands
RESULTS: There was no difference in the occurrence of the combined primary endpoint between the everolimus group and paclitaxel group at 30 days (3% vs. 4%, P=.20). Target vessel revascularization and target lesion revascularization were both lower in the everolimus group vs. paclitaxel group (0.6% vs. 2%, P=.004) at 30 days. At one year, the combined primary endpoint occurred in fewer patients receiving everolimus-eluting stents vs. those receiving paclitaxel-eluting stents (6% vs. 9%, P=.02). Target vessel revascularization was lower in patients receiving everolimus-eluting stents (2% vs. 6%, P<.0001), as was target lesion revascularization (2% vs. 5%, P<.0001). All-cause mortality (5% vs. 7%, P=.05) and stent thrombosis (0.7% vs. 3%, P=.002) were also lower in the everolimus group vs. the paclitaxel group at one year.
Published in: Lancet. 2009;doi:10.1016/S0140-6736(09)62127-9.
Click here to read more about the COMPARE trial.